Scalper1 News
Biotech Opko Health found a big-pharma partner for its human-growth drug candidate in the form of Pfizer on Monday in a deal that could be worth as much as $570 million. Opko Health (OPK) stock was near 9, up 9% in morning trading — a more than three-month high — on the stock market today. The deal between Opko and Pfizer (PFE) concerns hGH-CTP, a long-acting form of human growth hormone (hGH) intended to treat adults and children with stunted Scalper1 News
Scalper1 News